[CAR-T.]

Livia Donzelli1, Alice Di Rocco1

  • 1Ematologia, Dipartimento di Medicina traslazionale e di precisione, Sapienza Università di Roma.

PubMed
概括

一名患有复发性大B细胞淋巴瘤的患者在接受了axicabtagene ciloleucel (axi-cel) CAR-T疗法作为二线治疗后,获得了持续的完整代谢反应. 这一案例突出了高风险患者中axi-cel的疗效和可控毒性.

相关概念视频

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...